Plus   Neg

Heineken Shareholders Adopt All Proposals

Dutch brewer Heineken NV (HKHHF.PK) said that its Annual General Meeting of Shareholders has adopted all proposals on the agenda of the AGM.

The AGM approved the appointment of Dolf van den Brink as member of the Executive Board of HEINEKEN for a period of four years. Dolf van den Brink will become Chairman of the Executive Board and CEO of HEINEKEN on 1 June 2020.

Jean-François van Boxmeer will step down as Chairman of the Executive Board and CEO of HEINEKEN. He will hand over his responsibilities to Dolf van den Brink on 1 June 2020.

The AGM approved the dividend proposal for the year 2019 of 1.68 euros per share. As an interim dividend of EUR 0.64 was paid on 8 August 2019, the final dividend will be 1.04 euros per share. The final dividend will be made payable on 7 May 2020.

The AGM resolved to adjust the remuneration policy for the Executive Board and adopt a remuneration policy for the Supervisory Board.

The AGM re-appointed Pamela Mars Wright as member of the Supervisory Board for a four-year term.

The AGM re-appointed Deloitte Accountants B.V. as external auditor for the financial year 2021.

The AGM adopted amendments to the articles of association to align with current statutory Dutch law and make textual improvements.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd. Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial.
Follow RTT